Cambridge Cognition Ltd.

Cambridge Cognition is a neuroscience technology company specializing in digital cognitive assessment platforms for central nervous system (CNS) clinical trials. With over 30 years of scientific validation and expertise, the company provides an end-to-end solution for pharmaceutical companies, contract research organizations, and academic institutions. Core offerings include CANTAB® touchscreen cognitive assessments, voice analysis for verbal cognitive testing, electronic questionnaires and scales, high-frequency testing capabilities, decentralized clinical trial management, and automated quality assurance for clinical scales. The platform supports remote patient monitoring and decentralized trial recruitment, enabling drug developers to conduct cognitive efficacy and safety assessments in clinical or home settings. Cambridge Cognition's assessments have been validated across 3,000+ peer-reviewed publications and 250+ disease indications, including Alzheimer's disease, ADHD, depression, Parkinson's disease, multiple sclerosis, and schizophrenia. The company serves as a trusted partner for detecting subtle cognitive changes and generating objective biomarkers to accelerate brain health research and drug development timelines.